---
kind: "unit"
title: "21"
title_heading: "Food and Drugs"
key: "ch9/schV/ptE"
level: "part"
label: "Part E"
heading: "General Provisions Relating to Drugs and Devices"
release: "119-102"
date: "2026-07-12"
url: "https://uscodex.org/usc/21/ch9-schV-ptE"
sections_count: 21
---

# Part E — General Provisions Relating to Drugs and Devices

Title 21 — Food and Drugs › Chapter 9 — Federal Food, Drug, and Cosmetic Act › Subchapter V — Drugs and Devices

## Sections

- [§360bbb. Expanded access to unapproved therapies and diagnostics](/usc/21/360bbb.md)
- [§360bbb–0. Expanded access policy required for investigational drugs](/usc/21/360bbb-0.md)
- [§360bbb–0a. Investigational drugs for use by eligible patients](/usc/21/360bbb-0a.md)
- [§360bbb–1. Dispute resolution](/usc/21/360bbb-1.md)
- [§360bbb–2. Classification of products](/usc/21/360bbb-2.md)
- [§360bbb–3. Authorization for medical products for use in emergencies](/usc/21/360bbb-3.md)
- [§360bbb–3a. Emergency use of medical products](/usc/21/360bbb-3a.md)
- [§360bbb–3b. Products held for emergency use](/usc/21/360bbb-3b.md)
- [§360bbb–3c. Expedited development and review of medical products for emergency uses](/usc/21/360bbb-3c.md)
- [§360bbb–4. Countermeasure development, review, and technical assistance](/usc/21/360bbb-4.md)
- [§360bbb–4a. Priority review to encourage treatments for agents that present national security threats](/usc/21/360bbb-4a.md)
- [§360bbb–4b. Medical countermeasure master files](/usc/21/360bbb-4b.md)
- [§360bbb–5. Critical Path Public-Private Partnerships](/usc/21/360bbb-5.md)
- [§360bbb–5a. Emerging technology program](/usc/21/360bbb-5a.md)
- [§360bbb–6. Risk communication](/usc/21/360bbb-6.md)
- [§360bbb–7. Notification](/usc/21/360bbb-7.md)
- [§360bbb–8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments](/usc/21/360bbb-8.md)
- [§360bbb–8a. Optimizing global clinical trials](/usc/21/360bbb-8a.md)
- [§360bbb–8b. Use of clinical investigation data from outside the United States](/usc/21/360bbb-8b.md)
- [§360bbb–8c. Patient participation in medical product discussion](/usc/21/360bbb-8c.md)
- [§360bbb–8d. Notification, nondistribution, and recall of controlled substances](/usc/21/360bbb-8d.md)